

## Prescribing Clinical Network

<b>Policy Statement</b>	Toujeo (insulin glargine 300units/ml) in type II diabetes
<b>Policy No:</b>	PCN 182 -2016 (clarified February 2018)
<b>Date of Issue</b>	February 2016
<b>Review Date:</b>	February 2019 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<b>Recommendations:</b> <p>The PCN recommends the use of Toujeo (insulin glargine 300units/ml) in type II diabetes in the following circumstances:</p> <p>A: To be initiated by diabetes consultants or those GPs with specialist interest in diabetes, only in those poorly controlled patients:</p> <ul style="list-style-type: none"> <li>• Who do not reach their target HbA1c because of significant hypoglycaemia OR</li> <li>• Who experience significant hypoglycaemia on Neutral Protamine Hagedorn (NPH) and insulin detemir or glargine (100units/ml) irrespective of the level of HbA1c OR</li> <li>• Who cannot use the device needed to inject NPH and insulin detemir or glargine (100units/ml) but who could administer their own insulin safely and accurately if a switch to one of the long acting insulin analogues was made OR</li> <li>• Who need help from a carer or healthcare professional to administer insulin injections and for whom having a 3 hour window for daily administration is essential.</li> </ul> <p>B: For those patients currently receiving Humulin R U-500, consider switch to Toujeo</p> <p>Toujeo (insulin glargine 300units/ml) in type II diabetes will be considered as <b>AMBER*</b> on the traffic light system</p>	
<b>Key Consideration:</b> <ul style="list-style-type: none"> <li>• High strength, once daily injection.</li> <li>• Statistically significant reduction in confirmed or severe nocturnal hypoglycaemia in EDITION 1 &amp; EDITION 2 (compared with Lantus) but not in EDITION 3.</li> <li>• The members also noted the NICE guidance NG28 Type 2 diabetes in adults-management, that had been recently published (December 2015), which recommends when insulin therapy should be initiated and identifies a number of insulin types and regimens.</li> </ul>	
<b>Date taken to Prescribing Clinical Network</b>	February 2016
<b>Agreed by PCN members</b>	Updated and agreed by members February 2018

**Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG) Crawley and Horsham & Mid-Sussex CCG**